Search

Novo Nordisk A-S (Class B)

Cerrado

341.35 -0.28

Resumen

Variación precio

24h

Actual

Mínimo

340.8

Máximo

343.3

Métricas clave

By Trading Economics

Ingresos

-2.5B

27B

Ventas

-1.2B

77B

P/B

Media del Sector

14.432

37.461

BPA

5.96

Rentabilidad por dividendo

3.4

Margen de beneficios

34.484

Empleados

78,387

EBITDA

44B

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+9.53% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.40%

2.33%

Próximas Ganancias

5 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

138B

1.5T

Apertura anterior

341.63

Cierre anterior

341.35

Novo Nordisk A-S (Class B) Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2025, 10:26 UTC

Principales Movimientos del Mercado

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

17 oct 2025, 10:25 UTC

Principales Movimientos del Mercado

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 oct 2025, 15:36 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 oct 2025, 13:27 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

9 oct 2025, 10:49 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

22 oct 2025, 10:45 UTC

Ganancias

AI Stocks Aren't the Only Market Play. How -2-

22 oct 2025, 10:45 UTC

Ganancias

AI Stocks Aren't the Only Market Play. How Earnings Are Easing Recession Fears. -- Barrons.com

17 oct 2025, 10:10 UTC

Principales Movimientos del Mercado

Ozempic Maker Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs

15 oct 2025, 12:33 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 oct 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 oct 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 oct 2025, 12:32 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

10 oct 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

Bristol Myers Squibb Buys Private Biotech for $1.5 Billion. The Deal Wave Keeps Going. -- Barrons.com

10 oct 2025, 13:03 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Novo Nordisk's Akero Deal Makes Sense But Raises Questions -- Market Talk

9 oct 2025, 15:17 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk Is Buying Akero Therapeutics. It's More Good News for Biotech Stocks. -- Barrons.com

9 oct 2025, 11:31 UTC

Adquisiciones, fusiones, absorciones

Akero Therapeutics Stock Soars. Novo Nordisk Is Buying the Biotech for up to $5.2 Billion. -- Barrons.com

9 oct 2025, 10:34 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2B

9 oct 2025, 10:07 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk Says Metabolic Dysfunction-Associated Steatohepatitis is Closely Linked With Diabetes and Obesity

9 oct 2025, 10:05 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk: Akero is Developing Treatment For Liver Disease Metabolic Dysfunction-Associated Steatohepatitis

9 oct 2025, 10:04 UTC

Adquisiciones, fusiones, absorciones

Akero: Each CVR to Entitle Holder to Cash Payment of $6/Shr Upon Full U.S. Regulatory Approval of Efruxifermin for Treatment of Compensated Cirrhosis Due to MASH by June 30, 2031 >AKRO

9 oct 2025, 10:03 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk To Buy Akero Therapeutics for $4.7B in Cash, Plus Potentially an Additional $500M

9 oct 2025, 10:01 UTC

Adquisiciones, fusiones, absorciones

Novo Nordisk Agrees to Buy Akero Therapeutics For $54 a Share

7 oct 2025, 09:15 UTC

Charlas de Mercado

Novo Nordisk Consensus 2027 Sales Expectations Look Too High -- Market Talk

1 oct 2025, 09:05 UTC

Acciones populares

Stocks to Watch Wednesday: Nike, Lithium Americas, Arm, Occidental -- WSJ

29 sept 2025, 12:04 UTC

Charlas de Mercado

Novo Nordisk Faces Headwind as U.S Obesity Drugs Stall, Competition Rises -- Market Talk

22 sept 2025, 13:43 UTC

Adquisiciones, fusiones, absorciones

Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion -- Update

18 sept 2025, 12:30 UTC

Charlas de Mercado

Correction to Novo Nordisk Market Talk

18 sept 2025, 12:00 UTC

Charlas de Mercado

Novo Nordisk's Prospects Could Turn Around -- Market Talk

18 sept 2025, 08:55 UTC

Acciones populares

Stocks to Watch Thursday: Nvidia, PayPal, Novo Nordisk -- WSJ

Novo Nordisk A-S (Class B) previsión

Precio Objetivo

By TipRanks

9.53% repunte

Estimación a 12 Meses

Media 1,162.73 DKK  9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Novo Nordisk A-S (Class B) Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

7

Comprar

2

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
help-icon Live chat